Search This Blog

Thursday, March 9, 2017

Amgen Highlights Landmark Repatha® (Evolocumab) Cardiovascular Outcomes Study Amongst Data To Be Presented At ACC.17

Additional Presentations Include an Assessment of Repatha's Effect on Cognitive Function and Challenges Associated With Access to PCSK9 Inhibitor Therapy
Late-Breaking Repatha Presentations Will be Webcast Live


Amgen - Investors - RSS Content
Posted by at
Labels:

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)